Table 4.
Cox proportional hazards analysis of progression-free survival and overall survival.
| Variables | Progression-free survival |
Overall survival |
||
|---|---|---|---|---|
| HR (95%Cl) | P | HR (95%Cl) | P | |
| Age | 1.010 (0.984–1.036) | 0.465 | 1.036 (1.006–1.066) | 0.017 |
| ECOG status | 0.006 | 0.008 | ||
| 0 | Reference | Reference | ||
| 1 | 1.865 (1.021–3.404) | 0.042 | 0.706 (0.238–2.094) | 0.531 |
| 2 | 2.572 (1.025–6.457) | 0.044 | 1.437 (0.489–4.220) | 0.510 |
| 3 | 2.948 (1.569–5.538) | 0.001 | 3.656 (1.823–6.304) | 0.009 |
| Docetaxel regimens | 0.701 | 0.672 | ||
| Weekly | Reference | Reference | ||
| Biweekly | 1.232 (0.661–2.298) | 1.083 (0.601–1.951) | 0.791 | |
| Triweekly | 1.016 (0.579–1.782) | 0.881 (0.521–1.490) | 0.636 | |
| Chemotherapy response | 2.543 (1.305–4.953) | 0.006 | 1.881 (1.102–3.212) | 0.021 |
| Chemotherapy cycle | 0.886 (0.833–0.942) | 0.000 | 0.875 (0.828–0.925) | 0.000 |
ECOG, eastern cooperative oncology group.